Veradermics, Incorporated
- Market cap
- $4.84B
- 52w range
- $32.00 - $131.24
- Sector
- Healthcare
- Data quality
- 58/100
- fair value estimate
- $46.34
- Margin of safety
- -60.3%
- Moat score
- 16/100
- Analyst target
- $163.50
- Target upside
- +40.0%
- Analysts
- 6
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Valuation
Derived from filed metrics · Moderate confidence (58% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).